百奥泰生物制药股份有限公司 2025 年半年度募集资金存放、管理与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》和《上海证券交易所科创板股票上市规则》等有关规定， 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）董事会对 2025 年 半年度募集资金存放、管理与实际使用情况专项报告说明如下： 证券代码：688177 证券简称：百奥泰 公告编号：2025-054 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 经上海证券交易所科创板上市委员会 2019 年 11 月 20 日审核同意，并经中 国证券监督管理委员会 2020 年 1 月 14 日《关于同意百奥泰生物制药股份有限公 司首次公开发行股票注册的批复》(证监许可[2020]92 号)注册同意，本公司公开 发行人民币普通股 60,000,000 股，发行价格为人民币 32.76 元/股。募集资金总额 为人民币 1,965,600, ...

格隆汇8月20日丨百奥泰(688177.SH)公布，于近日收到了欧洲药品管理局（称"欧洲EMA"）签发的关于 Usymro®（BAT2206，乌司奴单抗注射液）上市批准通知。 ...

Core Viewpoint - The company has decided to adjust its development strategy for the biosimilar BAT3306, originally planned to terminate the BAT3306-2 study, in response to the latest technical guidance from the FDA and EMA [1] Group 1: Development Strategy - The company will conduct new registration clinical studies comparing BAT3306 with US-approved Keytruda in non-small cell lung cancer patients during the IB-IIIA phase [1] - The adjustment in strategy will not affect the fundraising investment plans or harm the interests of the company and its shareholders [1]

Core Viewpoint - The company Baiotai's product, Usymro (Ustekinumab injection), has received marketing approval from the European Medicines Agency (EMA) for the treatment of moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderate to severe active Crohn's disease (CD) [1] Group 1 - The approval of Usymro will further expand the company's international market presence and enhance the product's global influence [1] - The product is already in the commercialization process in several regions, including the United States, Russia, Brazil, and the European Union [1] - This approval is expected to have a positive impact on the company's long-term operational performance [1]

百奥泰生物制药股份有限公司2025 年半年度报告 公司代码：688177 公司简称：百奥泰 百奥泰生物制药股份有限公司 2025 年半年度报告 1 / 241 百奥泰生物制药股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述公司核心竞争力风险、经营风险、行业风险和宏观环境风险等因 素，敬请查阅本报告第三节"管理层讨论与分析"之"四、风险因素"。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人LI SHENGFENG（李胜峰）、主管会计工作负责人占先红及会计机构负责人（会 计主管人员）史利华声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、发展战略等前瞻性陈述，不构成公司对投资者的实质承 ...

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 30.229 billion yuan, while the Sci-Tech Innovation Board saw a net inflow of 730 million yuan [1] - A total of 252 stocks had net inflows, while 335 stocks had net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 359 stocks rose, with two stocks hitting the daily limit up, including Shengke Communication and Haocen Software, while 218 stocks fell [1] - The top three stocks with the highest net inflow of funds were Haiguang Information (1.084 billion yuan), Han's Laser (837 million yuan), and SMIC (385 million yuan) [1] Continuous Fund Flow - There were 49 stocks with continuous net inflows for more than three trading days, with Huahai Qingke leading at eight consecutive days of inflow [1] - Conversely, 133 stocks experienced continuous net outflows, with Fudan Zhangjiang and Qi Anxin both seeing 13 consecutive days of outflow [1] Top Fund Inflows - The top stocks by net inflow included: - Haiguang Information: 1.084 billion yuan, 14.77% inflow rate, 4.75% increase [1] - Han's Laser: 837 million yuan, 6.76% inflow rate, 8.46% increase [1] - SMIC: 385 million yuan, 4.97% inflow rate, 3.28% increase [1] Notable Outflows - The stocks with the highest net outflows included: - Dongxin Co., Ltd.: 366 million yuan outflow, 3.75% decrease [1] - Sainuo Medical: 305 million yuan outflow [1] - Yishitong: 177 million yuan outflow [1]

Core Viewpoint - The announcement details the share reduction plan executed by shareholders of Baotai Biopharmaceutical Co., Ltd., highlighting the completion of the reduction and the current shareholding status of the involved parties [1][4]. Group 1: Shareholder Information - Before the reduction plan, Xinyu Qiheng Management Consulting Partnership (Limited Partnership) and its acting in concert party, Huitianze Investment Co., Ltd., collectively held 20,704,000 shares, accounting for 5.00% of the total share capital of Baotai Biopharmaceutical [2]. Group 2: Reduction Plan Implementation - The reduction plan disclosed on April 24, 2025, allowed Xinyu Qiheng to reduce up to 8,281,600 shares, representing no more than 2% of the total share capital, with a maximum of 4,140,800 shares to be sold via centralized bidding and another 4,140,800 shares through block trading [3]. - The reduction period was set to commence 15 trading days after the announcement and would last for three months, with adjustments to the number of shares to be reduced in case of any capital changes [3]. Group 3: Reduction Results - As of August 19, 2025, Xinyu Qiheng reported a reduction of 3,216,877 shares through centralized bidding, which is 0.78% of the total shares, with no shares sold via block trading [4]. - Post-reduction, Xinyu Qiheng and Huitianze collectively hold 17,487,123 shares, which is 4.22% of the total share capital [4]. - The reduction plan was completed as scheduled, and the actual reduction matched the previously disclosed plan [5][6].

2024年1至12月份，百奥泰的营业收入构成为：医药制造占比100.0%。 百奥泰（SH 688177，收盘价：33.97元）8月19日晚间发布公告称，公司于2025年8月19日收到股东新余 启恒和汇天泽出具的《减持计划时间届满暨减持结果告知函》，新余启恒在本次减持计划中通过集中竞 价方式减持公司股份约322万股，减持股份数量占公司股份总数的0.78%，未通过大宗交易方式减持公 司股份。截至本公告披露日，本次减持计划时间区间届满，本次减持计划已实施完毕。 （文章来源：每日经济新闻） ...

证券代码：688177 证券简称：百奥泰 公告编号：2025-050 届满暨减持结果告知函》，新余启恒在本次减持计划中通过集中竞价方式减持公 司股份 3,216,877 股，减持股份数量占公司股份总数的 0.78%，未通过大宗交易 方式减持公司股份。本次权益变动后，东台启恒及一致行动人汇天泽合计持有公 司股份 17,487,123 股，占公司总股本的 4.22%。 百奥泰生物制药股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东的基本情况 本次减持计划实施前，新余市启恒管理咨询合伙企业（有限合伙）（曾用名： "东台市启恒医药合伙企业（有限合伙）""珠海吉富启恒医药投资合伙企业（有 限合伙）"，以下简称"新余启恒"）及其一致行动人汇天泽投资有限公司（以下 简称"汇天泽"）合计持有百奥泰生物制药股份有限公司（以下简称"公司"） 20,704,000 股，占公司总股本 5.00%，其中流通股股份数量为 20,704,000 股，占 公司总股本 5.00%。 减持计 ...

格隆汇8月19日丨百奥泰(688177.SH)公布，公司于2025年8月19日收到股东新余启恒和汇天泽出具的 《减持计划时间届满暨减持结果告知函》，新余启恒在本次减持计划中通过集中竞价方式减持公司股份 321.69万股，减持股份数量占公司股份总数的0.78%，未通过大宗交易方式减持公司股份。本次权益变 动后，东台启恒及一致行动人汇天泽合计持有公司股份1748.71万股，占公司总股本的4.22%。截至本公 告披露日，本次减持计划时间区间届满，本次减持计划已实施完毕。 ...